Scientific and Clinical Advisory Board

Curative Biotechnology, Inc.

Michael Grace, Ph.D

Chairman of the Scientific and Clinical Advisory Board

Michael Grace has 30 years of executive and technical experience in both research and development of protein therapeutics and peptides within the biotechnology industry at Schering-Plough, Bristol Myers Squibb, NPS Pharma and Advaxis Inc.

He has contributed to or personally led the development to commercial approval of 9 drugs by FDA and EMA including PEG-IntronTM, OrenciaTM, NulojixTM, YervoyTM, GattexTM and NatparaTM. His experience encompasses all aspects of drug development from discovery, process development, analytical development, quality control and regulatory. He is well-published within his field of expertise and has presented world-wide on several aspects of protein analytics, characterization, and process and product development.

Ronald Bordens, Ph.D

Executive Vice President - Process Product Drug Development

Ronald Bordens is an accomplished executive scientist with over 40 years of successful experience in biotechnology and pharmaceutical industries for companies focused on research and development.

He possesses a unique skill set including but not limited to people leadership, scientific expertise, and quality assurance and control. His pharmaceutical industry experience includes drug discovery, drug development and research technology with a focus on bioanalytical research, biomarkers, and leadership development from his 26-year career at Schering-Plough Research.

Dr. Barry A. Ginsberg

Chief Strategy Officer and Vice Chairman

Dr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care which includes the diagnosis, treatment, management and prevention of diseases of the eye and visual system. Dr. Ginsberg has also participated in new Ophthalmic Drug and Procedure development trials utilizing his vast patient database.

Combined with an extensive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.

Dr. Ginsberg earned his Bachelor’s of Arts degree in Chemistry with a minor in Economics from Yeshiva University, and his Bachelor of Science and Doctorate degrees from the Pennsylvania College of Optometry. Concurrently, he attended the LaSalle College MBA Program in Philadelphia. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on age-related macular degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including glaucoma.

Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field.